ORTX Orchard Rx ADS

Orchard Therapeutics to Webcast Conference Call of First Quarter 2020 Financial Results

Orchard Therapeutics to Webcast Conference Call of First Quarter 2020 Financial Results

BOSTON and LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to report its first quarter 2020 financial results and other business updates.

A live webcast will be available under "News & Events" in the Investors & Media section of the company's website at orchard-tx.com. The conference call can be accessed by dialing (866) 987-6504 (U.S. domestic) or +1 (602) 563-8620 (international) and referring to conference ID 8348144. A replay of the webcast will be archived on the Orchard website following the presentation.

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy product candidate pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders, where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit , and follow us on and .

Contacts

Investors

Renee Leck

Director, Investor Relations



EN
01/05/2020

Underlying

ORTXOrchard Rx ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orchard Rx ADS

 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidars...

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy Five specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist patient services program to provide individualized support throughout the treatment process Lenmeldy wholesale acquisition cost of $4.25 million for one-time treatment reflects its clinical, economic and societal value Innovative outcomes- and value-based agreements...

March 20, 2024 1 EN
 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene ...

Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) TOKYO and LONDON and BOSTON, March 18, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced the U....

March 18, 2024 1 EN
 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Announces First Patient Randomized in Registratio...

Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S. and Europe TOKYO, LONDON and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients ar...

February 5, 2024 1 EN
 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Announces Multiple Presentations at the 20th Annu...

Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced 10 presentations from across its neurometabolic portfolio will be featured at the 20th Annual W...

February 2, 2024 1 EN
 PRESS RELEASE
Free
ORTX ORCHARD RX ADS

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium ...

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD). The agreement covers several member countries, including Belgium, The Ne...

January 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch